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Table
Pediatric HSCT Blood Pressure Data (Day +0 to Day +5)
Number of pediatric HSCT patients 6
Patients age 6 month-14 years
Type of HSCT allogeneic matched
unrelated donor
Number of myeloablative HSCT 2 of 6
Number of reduced intensity HSCT 4 of 6
Number of patients with initial BP
parameters ordered that were above
>95% for age and height or above
age speciﬁc percentiles for birth to
12 months of age
3/6
Total number of blood pressure (BP) data
points (Day +0 to Day +5)
458
Median number of elevated systolic BPs
documented before a BP medication
was ﬁrst ordered
30
Median number of diastolic BPs
documented before a BP medication
as ﬁrst ordered
16
Median Time in hours to Initial
antihypertensive medication delivery
after elevated BPs were documented
64.5
Most frequently used antihypertensive
medications
Hydralazine (as needed)
Nicardipine (as needed)
Amlodipine
(1-2 times daily)
Enalaprilat (every
8 hours)
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based on a history and physical, review of a Health History
Questionnaire (HHQ), and various diagnostic tests. The
Foundation for the Accreditation of Cellular Therapy (FACT),
set standards of operation to promote quality medical and
laboratory practice in hematopoietic transplantation and
other cellular therapy products. Adherence to the FACT
standards helps to ensure donor eligibility thereby reducing
the risks of transmissible diseases. The HHQ guides the NP in
determining donor eligibility. A retrospective chart review of
46 medical records from January 2011 through December
2011 revealed the rate of accuracy of 60% in determining
donor eligibility based upon FACT criteria. All donors (46)
were deemed as eligible; however, only 28 met FACT criteria
for eligibility. Eighteen patients were ineligible; yet they
were medically acceptable to donate. Reasons for ineligibility
included: a missing or incomplete HHQ, a tattoo within
a year, donor lived in Europe. NPs were re-educated
regarding FACT criteria and how to use the HHQ when
determining eligibility. A tool provided a guideline for the
NPs highlighting special considerations for donors that
would make them potentially ineligible. Following these
interventions, the rate of accuracy improved to 84%. From
June 2012 to September 2012, 19 medical records were
reviewed 16 met FACT criteria for eligibility. By re-educating
NPs about FACT guidelines, NPs were able to utilize the HHQ
as a crucial step in their assessment process and improve the
rate of accuracy in determining donor eligibility thus
improving donor screening.502
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Hypertension (HTN) is a known complication of pediatric
hematopoietic stem cell transplant (HSCT). Historically, the
risks for developing HTN depend on a variety of factors which
may includeuseof calcineurin inhibitors, thepresenceof graft
versus host disease requiring steroid therapy, total body
irradiation, and standardized chemotherapy delivered during
HSCT. Uncontrolled HTN in pediatric HSCT patients may lead
to signiﬁcant life threatening complications that often affect
long term cardiac and renal outcomes. Managing pediatric
HSCT associated HTN is often a challenge due to the range of
patients ages, heights and weights which determine normal
and target blood pressure. Using a multidisciplinary
approach, we collected pilot data from 6 pediatric patients
whohad received allogeneicHSCTs fromday +0 to day +5. The
focus was to look at their hypertension management within
the ﬁrst days following their stem cell infusions. The data
consisted of blood pressure parameters ordered, documented
blood pressures, the response time for reporting HTN and the
antihypertensive medications given to patients during that
period. The table below lists the data obtained. We found 3
areas to focus improvements on. One was to educate staff on
the use of the individualized blood pressure parameters(<95% for age and height, Pediatrics 2004; 114; 555-576,
infants birth -12 months parameters, Pediatric Nephrology
(2012) 27:17-32) in the initial order set. A second area was to
educate staff on the process of taking blood pressures
according to the published guidelines followed by our
nephrology and HTN clinics. A third improvement opportu-
nitywas to decrease the time to initiation of antihypertensive
therapy. Overall the goal is to protect the pediatric patients
throughout HSCT. This is a process that the multidisciplinary
HSCT team continues to focus and improve upon, thus
impacting the outcomes for our pediatric BMT population.
503
Individualized Care Planning Process
Lourine Davis 1, Colleen Villamin 2, Roxann Blackburn 3,
Buenagracia de la Cruz 2, Nancy Tomczak 4. 1M.D. Anderson
Cancer Center, Houston, TX; 2 UT MD Anderson Cancer Center,
Houston, TX; 3 UT MD Anerson Cancer Center, Houston, TX;
4 The University of Texas MD Anderson Cancer Center, Houston,
TX
Background: At an NCI-designated Cancer Institution with
76 inpatient stem cell transplant (SCT) patients and a bur-
geoning staff, addressing continuity of care and patient
satisfaction is an on-going opportunity for growth and
innovation. Press-Ganey patient satisfaction data revealed
that patients wanted more consistency in care, improved
communication, and increased involvement in their treat-
ment plan. In response, a nurse-driven, patient-centered
initiative examined the efﬁcacy of creating individualized
care plans, customized to each patient's unique needs, in
collaboration with the patient and caregivers.
Purpose: To increase consistency of care, improve commu-
nication among nurses and patients, and raise patient satis-
faction, a nurse-developed and driven Individualized Care
Planning Process (ICPP) was developed.
Intervention: The ICPP engages nurse volunteers to be
responsible for thedevelopmentand trackingof individualized
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identiﬁed or were identiﬁed by their clinical nurse as poten-
tially beneﬁtting from the ICPP. Once identiﬁed, care plans are
developed to address patient concerns, psychosocial factors,
physical needs, daily routine, activity, nutrition, abnormal
assessment ﬁndings, nursing interventions, discharge plan-
ning, short and long term goals. Copies of the care plan are
given to the patient and placed with the nursing documenta-
tion to improve communication. Concurrently, monthly ICPP
meetings are conducted with nurse ICPs to identify patients
who need care plans, address challenges faced, and discuss
literature that supports the need for providing patient-
centered care.
Evaluation: The ICPP initiative is evaluated through two
sources, the ﬁrst a ﬁve question quality improvement ques-
tionnaire utilizing Likert Scale responses to determine
patient satisfaction with nurse communication, responsive-
ness, shared decision-making, and the individualized care
plan. In addition, Quarterly analysis includes comparing
Press Ganey Patient Satisfaction scores pre and post ICP
implementation and comparing ICP survey scores to Press
Ganey scores. Quality improvement data collected from June
1st, 2012- December 31st, 2012 will be presented to examine
the efﬁcacy of the ICPP on patient satisfaction scores.
Discussion: The ICPP initiative is a creative, nurse-driven
initiative to address patient satisfaction during prolonged
admissions for SCT treatment and complications. Preliminary
quality improvement data demonstrates improvement in
overall patient satisfaction scores across a 76-bed inpatient
SCT service at an NCI-designated cancer center. The ICPP
process may prove beneﬁcial and adoptable across SCT care
settings in addressing and improving patient satisfaction.504
Managing Skin and Wound Care on a BMT Unit
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Signiﬁcance & Background: As products and treatments
change forwounds and pressure ulcers, BMT nurses are faced
with the lack of knowledge and comfort to care for these
types of changes. With the development of unit experts
through a hospital supported program our unit recognized
an increased problem with incontinence associated derma-
titis commonly caused by unmanaged diarrhea from treat-
ment. Diarrhea leads to an increase in skin breakdown and
wounds; putting patients at risk for infection and pain. Our
unit also noted that nurses lacked the general knowledge of
how to prevent, stage and treat pressure ulcers as well as
incontinence associated dermatitis.
Purpose: The purpose of the project was to increase the BMT
nurses knowledge and comfort of skin andwound care issues
commonly found on a BMT unit. A special emphasis was
placed on pressure ulcers and incontinence associated
dermatitis.
Interventions: Ongoing education of unit experts was sup-
ported and encouraged by a hospital supported program. A
quarterly newsletter was distributed to staff with reminders
and updates on pressure ulcers and IAD. Staff was mandated
to read the updates. A skin cupboard with supplies and a skin
binder was developed to be used as a resource for nurses. A
checklist was developed to help the nurses comply with
hospital policy for pressure ulcer assessment, documenta-
tion, and management. A twenty minute power point
presentation focusing on pressure ulcers and IAD was
developed and provided to staff at staff meetings and in-
services throughout the year.Evaluation: A survey was sent to the nurses to determine
their knowledge level and comfort on wounds and inconti-
nence associated dermatitis before and after the
interventions.
Discussion: Ongoing development and reinforcement is
needed for BMT nurses to gain comfort and increase their
knowledge with pressure ulcers and IAD. Recruiting and
retaining wound experts is an ongoing issue.505
Examining the Evidence for Frequency of Vital Sign
Monitoring During Transfusion of Blood Products in the
Stem Cell Transplant Patient Population
Karen Terry DeYoung, Truc Vu. Stem Cell Transplant, M. D.
Anderson Cancer Center, Houston, TX
Background: Patients undergoing stem cell transplantation
(SCT) receive copious amounts of blood products during the
course of treatment. This alone can be disruptive to patients
and is further compounded by taking frequent vital signs
during blood transfusions. Current policy on a large SCT unit
is to take routine vital signs every four hours. During blood
transfusions, vital signs are taken at baseline, 10-15 minutes
after initiation, hourly, and 30 minutes after blood adminis-
tration is complete. Such frequent vital sign monitoring
interrupts sleep and the patient's ability to ambulate or
participate in unit activities, consequently affecting inpatient
stay and satisfaction. Additionally, frequent vital signs
monitoring can be uncomfortable for patient and time
consuming for nurses. The decision for the frequency of vital
sign monitoring is arbitrary, as the current policy is not
evidence based. Relying heavily on vital signs may affect
nursing judgment by becoming too focused on measuring
vital signs and overlooking other non-measurable
symptoms.
Aim/Objective: The staff nurses of a SCT unit identiﬁed the
need to examine the evidence in the literature regarding the
optimum frequency of vital sign monitoring for SCT patients
receiving blood products in relationship to the institution's
current policy.
Intervention: An evidenced-based project was developed to
review current evidence on frequency of vital signs for SCT
patients receiving blood products and comparing those
results to the current policy. The literature reviewed suggests
that taking vital signs before blood transfusions, after ﬁfteen
minutes, and upon completion was clinically sound. In
addition, the literature also supported patient observation as
a key method to assess blood transfusion-related reactions
rather than relying on vital signs alone. All literature
reviewed supported taking vital signs at baseline and after
ﬁfteen minutes, as this is the time period in which a reaction
would most likely occur. In addition, better training of staff
was recommended to recognize a blood reaction should it
occur.
Results/Evaluation: Findings were presented to the Nurse
Practice Congress and a decision to form a PACT was made to
investigate making an institutional policy change. A multi-
disciplinary group is meeting to pursue this change in prac-
tice.506
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